SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-008318
Filing Date
2024-05-15
Accepted
2024-05-15 17:15:37
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20240331x10q.htm   iXBRL 10-Q 1475202
2 EX-3.1 otlk-20240331xex3d1.htm EX-3.1 47964
3 EX-3.2 otlk-20240331xex3d2.htm EX-3.2 15417
4 EX-31.1 otlk-20240331xex31d1.htm EX-31.1 9602
5 EX-31.2 otlk-20240331xex31d2.htm EX-31.2 12098
6 EX-32.1 otlk-20240331xex32d1.htm EX-32.1 9499
  Complete submission text file 0001558370-24-008318.txt   7278214

Data Files

Seq Description Document Type Size
7 EX-101.SCH otlk-20240331.xsd EX-101.SCH 44578
8 EX-101.CAL otlk-20240331_cal.xml EX-101.CAL 36096
9 EX-101.DEF otlk-20240331_def.xml EX-101.DEF 241095
10 EX-101.LAB otlk-20240331_lab.xml EX-101.LAB 393214
11 EX-101.PRE otlk-20240331_pre.xml EX-101.PRE 351925
73 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20240331x10q_htm.xml XML 1300400
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 24952556
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)